Approved in patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan.
Approval based on data from the ongoing Phase 2 CheckMate -142 study
The Opdivo + Yervoy combination approved in two other tumor types
